Market Overview

SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'

Share:
Related AZN
'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Primecap Sells NVIDIA, Microsoft, Union Pacific (GuruFocus)
Related PFE
PreMarket Prep Recap, March 21: We Haven't Seen A 2% Correction Since The Election
Anatomy Of A Decision, Part 1: The C-Suite
European advisory committee backs approval of Pfizer's meningococcal vaccine (Seeking Alpha)

Pfizer Inc. (NYSE: PFE) is likely to boost its offer for British drug maker AstraZeneca PLC (ADR) (NYSE: AZN) to $96.28 a share, an analyst said Tuesday.

SunTrust's John Boris said a deal would cut Pfizer's tax rate to 20 percent and said potential Treasury inversion action blocking such action is merely “election year rhetoric.”

The $127 billion offer envisioned by Boris would tack on 6.3 percent to its earlier bid of $120 billion, which AstraZeneca (NYSE: AZN) rejected back in mid-May

AstraZeneca's American Depositary Receipts were recently down two percent at $74.62 from Friday's high, but were still up nearly 26 percent for the year.

Under British rules, AstraZeneca can, starting Tuesday, invite it back for talks or Pfizer can make a single "knock-out" bid which it believes would be accepted. Pfizer (NYSE: PFE) can also start a more conventional bidding process over again, beginning in November.

Posted-In: John Boris SunTrustAnalyst Color News Rumors M&A

 

Related Articles (AZN + PFE)

View Comments and Join the Discussion!